(E)-4-methylhept-2-enoic acid

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (E)-4-methylhept-2-enoic acid
• 英文别名: (E)-4-methyl-hept-2-enoic acid
• 化学式: C₈H₁₄O₂
• 分子量: 142.198
• InChiKey: LUZDHFBIJYJLMK-AATRIKPKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (E)-4-methylhept-2-enoic acid 在 N-甲基吗啉 、 4-二甲氨基吡啶 、 二异丁基氢化铝 、 三乙胺 、 三氯氧磷 、 氯甲酸异丁酯 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 7.66h， 生成 2-(5-methyl-2-[(1E)-3-methylhex-1-enyl]oxazol-4-yl)ethyl methanesulfonate
  参考文献：
  名称：

  Novel (S)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids: Peroxisome proliferator-activated receptor γ selective agonists with protein-tyrosine phosphatase 1B inhibition

  摘要：

  A novel series of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives were synthesized and (S)-2-[(2E,4E)- hexadienoyl]-7-(2-(5-methyl-2-[( 1E)-5-methylhexen-1-yl]oxazol-4-yl]ethoxy)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (14i) was identified as a potent human peroxisome proliferator-activated receptor gamma (PPAR gamma) selective agonist (EC(50) = 0.03 mu M) and human protein-tyrosine phosphatase 1B (PTP-1B) inhibitor (IC(50) = 1.18 mu M). C(max) after oral administration of 14i at 10 mg/kg was 2.2 mu g/ml (4.5 mu M) in male SD rats. Repeated administration of 14i and rosiglitazone for 14 days dose-dependently decreased plasma glucose levels, ED(50) = 4.3 and 23 mg/kg/day, respectively, in male KK-A(y) mice. In female SD rats, repeated administration of 14i at 12.5-100 mg/kg/day for 28 days had no effect on the hematocrit value (Ht) and red blood cell count (RBC), while rosiglitazone significantly decreased them from 25 mg/kg/day. In conclusion, 14i showed about a fivefold stronger hypoglycemic effect and fourfold or more weaker hemodilution effect than rosiglitazone, indicating that 14i is 20-fold or more safer than rosiglitazone. Compound 14i is a promising candidate for an efficacious and safe anti-diabetic drug targeting PPAR gamma and PTP-1B. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.11.035
• 作为产物：
  描述：

  ethyl (E)-4-methylhept-2-enoate 在 乙醇 、 水 、 potassium hydroxide 作用下， 以85 %的产率得到(E)-4-methylhept-2-enoic acid
  参考文献：
  名称：

  发现噻吨酮-TfOH 络合物作为光氧化还原催化剂用于使用对二甲苯作为电子和氢源的烯烃加氢

  摘要：

  通过简单地将催化量的 TfOH 作为助催化剂添加到容易获得的噻吨酮中，发现了一种新型有机光氧化还原催化剂。新型催化剂9-HTXTF具有足够长的单线态寿命和足够强的氧化电位，以及相对容易的光激发，可用于羰基化烯烃的氢化和氘化。

  DOI：

  10.1002/anie.202211562

文献信息

• [EN] N-HETEROARYL COMPOUNDS WITH CYCLIC BRIDGING UNIT FOR THE TREATMENT OF PARASITIC DISEASES<br/>[FR] COMPOSÉS N-HÉTÉROARYLÉS AYANT UNE UNITÉ PONTANTE CYCLIQUE POUR LE TRAITEMENT DE MALADIES PARASITAIRES
  申请人：INTERVET INT BV

  公开号：WO2012041872A1

  公开（公告）日：2012-04-05

  This invention relates to certain N-heteroaryl compounds that are generally useful as medicaments, more specifically as medicaments for animals. The medicament can preferably be used for the treatment of helminth infections and the treatment of parasitosis, such as caused by helminth infections. This invention also relates to uses of the compounds to make medicaments and treatments comprising the administration of the compounds to animals in need of the treatments. This invention also relates to the preparation of the N-heteroaryl compounds. Moreover this invention relates to pharmaceutical compositions and kits comprising the compounds.

  这项发明涉及某些N-杂环芳基化合物，通常用作药物，更具体地用作动物药物。该药物可以优选用于治疗蠕虫感染和寄生虫病的治疗，例如由蠕虫感染引起的寄生虫病。该发明还涉及利用这些化合物制备药物和治疗方法，包括将这些化合物用于需要治疗的动物的给药。此外，该发明还涉及N-杂环芳基化合物的制备。此外，该发明还涉及包含这些化合物的药物组合物和试剂盒。
• N-heteroaryl compounds with cyclic bridging unit for the treatment of parasitic diseases
  申请人：Berger Michael

  公开号：US08883791B2

  公开（公告）日：2014-11-11

  This invention relates to certain N-heteroaryl compounds that are generally useful as medicaments, more specifically as medicaments for animals. The medicament can preferably be used for the treatment of helminth infections and the treatment of parasitosis, such as caused by helminth infections. This invention also relates to uses of the compounds to make medicaments and treatments comprising the administration of the compounds to animals in need of the treatments. This invention also relates to the preparation of the N-heteroaryl compounds. Moreover this invention relates to pharmaceutical compositions and kits comprising the compounds.

  本发明涉及某些N-杂环芳基化合物，通常作为药物使用，更具体地作为动物药物。该药物可优选用于治疗蠕虫感染和寄生虫病的治疗，例如由蠕虫感染引起的寄生虫病。本发明还涉及使用这些化合物制备药物和治疗方法，包括向需要治疗的动物施用这些化合物。本发明还涉及制备N-杂环芳基化合物，此外还涉及包含这些化合物的制药组合物和套装。
• N-HETEROARYL COMPOUNDS WITH CYCLIC BRIDGING UNIT FOR THE TREATMENT OF PARASITIC DISEASES
  申请人：Berger Michael

  公开号：US20130203768A1

  公开（公告）日：2013-08-08

  This invention relates to certain N-heteroaryl compounds that are generally useful as medicaments, more specifically as medicaments for animals. The medicament can preferably be used for the treatment of helminth infections and the treatment of parasitosis, such as caused by helminth infections. This invention also relates to uses of the compounds to make medicaments and treatments comprising the administration of the compounds to animals in need of the treatments. This invention also relates to the preparation of the N-heteroaryl compounds. Moreover this invention relates to pharmaceutical compositions and kits comprising the compounds.

  本发明涉及某些N-杂环芳基化合物，通常作为药物使用，更具体地作为动物药物。该药物可优选用于治疗蠕虫感染和寄生虫病的治疗，例如由蠕虫感染引起的寄生虫病。本发明还涉及使用该化合物制备药物和治疗方法，包括将该化合物用于需要治疗的动物的管理。本发明还涉及N-杂环芳基化合物的制备。此外，本发明还涉及包含该化合物的制药组合物和套装。
• Metzger, Juergen O.; Klenke, Kurt, Chemische Berichte, 1990, vol. 123, # 4, p. 875 - 879
  作者：Metzger, Juergen O.、Klenke, Kurt

  DOI：——

  日期：——
• SALTS OF PAROXETINE
  申请人：SMITHKLINE BEECHAM PLC

  公开号：EP1091958A1

  公开（公告）日：2001-04-18